Clinician compliance to recommendations regarding the risk of suicidality with selective serotonin reuptake inhibitors in the treatment of children and adolescents.

摘要: Meta-analyses of randomized-controlled trials have established a heightened risk suicidality for children and adolescents treated with selective serotonin reuptake inhibitors (SSRIs). The present study examined to what extent daily clinical practice complied specific recommendations regarding the when treating SSRIs. All in- outpatients aged 0–17 years at Child Adolescent Mental Health Services, Capital Region Denmark prescription SSRI on January 1st, 2016 were identified. Data obtained n = 365 patients level clinician compliance deliver pre-consent information about adverse effects, monitor suicidality, provide non-pharmacological interventions. 81.7% (n = 298) received effects. 67.7% (n = 247) monitored within 6 weeks after initiation. Children (0–13 years) less likely be compared (14–17 years) (49.6% vs. 77.5%, p < 0.001). Patients depression as indication treatment more than other indications (OR = 3.4, p = 0,002) receive specifically (34.7% 19.7%, p = 0.002). Respectively, 89.3% (n = 326) 93.4% (n = 341) all SSRI-treated interventions prior in parallel treatment. For majority cases, from guidelines. However, younger age and/or SSRIs managed according recommendations.